keyword
https://read.qxmd.com/read/38652340/poorly-differentiated-mucinous-carcinoma-of-the-ascending-colon-complicated-by-bilateral-ovarian-mature-cystic-teratomas-in-a-17-year-old-female-patient-a-case-report
#21
JOURNAL ARTICLE
Takuya Shimogawa, Yukiharu Hiyoshi, Mayuko Ouchi, Keisuke Kosumi, Kojiro Eto, Satoshi Ida, Masaaki Iwatsuki, Yoshifumi Baba, Yuji Miyamoto, Nasa Okazaki, Yuko Miyasato, Hideo Baba
BACKGROUND: Colorectal cancer (CRC) is one of the most common cancers worldwide, and screening colonoscopy has led to a decreasing incidence rate. However, the incidence of CRC is increasing among young people, especially adolescents and young adults (AYAs) who are not routinely screened. Although CRC is the fourth most common cancer among AYAs, it is extremely rare. In younger patients, CRC is often diagnosed later, and the proportion of patients with advanced CRC is higher than that in older patients...
April 23, 2024: Surgical Case Reports
https://read.qxmd.com/read/38652231/diagnostic-and-therapeutic-use-of-oral-micronized-progesterone-in-endocrinology
#22
REVIEW
Eleni Memi, Polina Pavli, Papagianni Maria, Nikolaos Vrachnis, George Mastorakos
Progesterone is a natural steroid hormone, while progestins are synthetic molecules. In the female reproductive system, progesterone contributes to the control of luteinizing hormone and follicle-stimulating hormone secretion and their pulsatility, via its receptors on the kisspeptin, neurokinin B, and dynorphin neurons in the hypothalamus. Progesterone together with estradiol controls the cyclic changes of proliferation and decidualization of the endometrium; exerts anti-mitogenic actions on endometrial epithelial cells; regulates normal menstrual bleeding; contributes to fertilization and pregnancy maintenance; participates in the onset of labor...
April 23, 2024: Reviews in Endocrine & Metabolic Disorders
https://read.qxmd.com/read/38652223/exploring-the-impact-of-pdgfd-in-osteosarcoma-metastasis-through-single-cell-sequencing-analysis
#23
JOURNAL ARTICLE
Yujing Huang, Dongyan Cao, Manxue Zhang, Yue Yang, Gengming Niu, Lina Tang, Zan Shen, Zhichang Zhang, Yueqing Bai, Daliu Min, Aina He
PURPOSE: The overall survival rate for metastatic osteosarcoma hovers around 20%. Responses to second-line chemotherapy, targeted therapies, and immunotherapies have demonstrated limited efficacy in metastatic osteosarcoma. Our objective is to validate differentially expressed genes and signaling pathways between non-metastatic and metastatic osteosarcoma, employing single-cell RNA sequencing (scRNA-seq) and additional functional investigations. We aim to enhance comprehension of metastatic mechanisms and potentially unveil a therapeutic target...
April 23, 2024: Cellular Oncology (Dordrecht)
https://read.qxmd.com/read/38652202/developing-a-novel-enzalutamide-resistant-prostate-cancer-model-via-ar-f877l-mutation-in-lncap-cells
#24
JOURNAL ARTICLE
Ruifeng Wang, Shuhua Ma, Nengwei Xu, Yumiao Gan, Pengya Li, Jingying Zhang, Zhixiang Zhang, Qingyang Gu, Jian Xiang
Prostate cancer is a leading diagnosis and major cause of cancer-related deaths in men worldwide. As a typical hormone-responsive disease, prostate cancer is commonly managed with androgen deprivation therapy (ADT) to curb its progression and potential metastasis. Unfortunately, progression to castration-resistant prostate cancer (CRPC), a notably more aggressive phase of the disease, occurs within a timeframe of 2-3 years following ADT. Enzalutamide, a recognized androgen receptor (AR) antagonist, has been employed as a standard of care for men with metastatic castration-resistant prostate cancer (mCRPC) since it was first approved in 2012, due to its ability to prolong survival...
April 2024: Current protocols
https://read.qxmd.com/read/38652192/bortezomib-suppresses-acute-myelogenous-leukaemia-stem-like-kg-1a-cells-via-nf-%C3%AE%C2%BAb-inhibition-and-the-induction-of-oxidative-stress
#25
JOURNAL ARTICLE
Rafaela G A Costa, Maiara de S Oliveira, Ana Carolina B da C Rodrigues, Suellen L R Silva, Ingrid R S B Dias, Milena B P Soares, Ludmila de Faro Valverde, Clarissa Araujo Gurgel Rocha, Rosane Borges Dias, Daniel P Bezerra
Acute myelogenous leukaemia (AML) originates and is maintained by leukaemic stem cells (LSCs) that are inherently resistant to antiproliferative therapies, indicating that a critical strategy for overcoming chemoresistance in AML therapy is to eradicate LSCs. In this work, we investigated the anti-AML activity of bortezomib (BTZ), emphasizing its anti-LSC potential, using KG-1a cells, an AML cell line with stem-like properties. BTZ presented potent cytotoxicity to both solid and haematological malignancy cells and reduced the stem-like features of KG-1a cells, as observed by the reduction in CD34- and CD123-positive cells...
April 2024: Journal of Cellular and Molecular Medicine
https://read.qxmd.com/read/38652185/survival-among-treated-tongue-cancer-patients-a-single-center-experience
#26
JOURNAL ARTICLE
Pablo Veiga-San Roman, Victor Villanueva San Vicente, M Angeles Rodriguez-Gonzalez, Pia López-Jornet
OBJECTIVE: To describe overall survival (OS) and disease-free survival (DFS) in a cohort of tongue cancer patients, together with the corresponding demographic, tumor and surgical characteristics. METHODS: A retrospective study was made of 205 consecutive patients with primary tongue cancer subjected to surgery and adjuvant therapy according to the stage of the disease, in Hospital Clínico Universitario Virgen de la Arrixaca (HUVA) (Murcia, Spain) during the period 2000-2020...
April 23, 2024: Discover. Oncology
https://read.qxmd.com/read/38652178/challenges-and-strategies-in-relation-to-effective-car-t-cell-immunotherapy-for-solid-tumors
#27
REVIEW
Guangxun Yuan, Mengke Ye, Yixi Zhang, Xun Zeng
Chimeric Antigen Receptor T cell (CAR-T) therapy has revolutionized cancer treatment, but its application to solid tumors is limited. CAR-T cells have poor incapability of entering, surviving, proliferating, and finally exerting function in the tumor microenvironment. This review summarizes the main strategies related to enhancing the infiltration, efficacy, antigen recognition, and production of CAR-T in solid tumors. Additional applications of CAR-γδ T and macrophages are also discussed. We believe CAR-T will be a milestone in treating solid tumors once these problems are solved...
April 23, 2024: Medical Oncology
https://read.qxmd.com/read/38652119/long-term-remission-after-upfront-autologous-hematopoietic-stem-cell-transplant-for-cd5-diffuse-large-b-cell-lymphoma
#28
JOURNAL ARTICLE
Yosuke Masamoto, Akira Honda, Aya Shinozaki-Ushiku, Tetsuo Ushiku, Mineo Kurokawa
CD5+ diffuse large B-cell lymphoma (DLBCL) is a rare subtype characterized by an inferior outcome. While dose-dense therapy shows promising activity, the optimal management remains to be determined. To evaluate the benefit of consolidative autologous hematopoietic stem cell transplantation (ASCT), we retrospectively reviewed the medical records of 47 consecutive patients with newly diagnosed de novo CD5+ DLBCL. Of 19 patients ≤ 70 of age with age-adjusted International Prognostic Index 2-3, eight underwent upfront ASCT, and nine did not, despite preserved organ function and response after induction therapy...
April 23, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38652103/recording-and-classifying-met-receptor-mutations-in-cancers
#29
REVIEW
Célia Guérin, David Tulasne
Tyrosine kinase inhibitors (TKI) directed against MET have been recently approved to treat advanced non-small cell lung cancer (NSCLC) harbouring activating MET mutations. This success is the consequence of a long characterization of MET mutations in cancers, which we propose to outline in this review. MET, a receptor tyrosine kinase (RTK), displays in a broad panel of cancers many deregulations liable to promote tumour progression. The first MET mutation was discovered in 1997, in hereditary papillary renal cancer (HPRC), providing the first direct link between MET mutations and cancer development...
April 23, 2024: ELife
https://read.qxmd.com/read/38652093/identification-of-ppar-related-differentially-expressed-genes-liver-hepatocellular-carcinoma-and-construction-of-a-prognostic-model-based-on-data-analysis-and-molecular-docking
#30
JOURNAL ARTICLE
Yumeng Wang, Shuqiang Li, Zihang Liu, Xuanzheng Li, Yifan Yu, Hao Liu
Liver hepatocellular carcinoma (LIHC) is a significant global health issue with limited treatment options. In this study, single-cell RNA sequencing (scRNA-seq) data were used to explore the molecular mechanisms of LIHC development and identify potential targets for therapy. The expression of peroxisome proliferator-activated receptors (PPAR)-related genes was analysed in LIHC samples, and primary cell populations, including natural killer cells, T cells, B cells, myeloid cells, endothelial cells, fibroblasts and hepatocytes, were identified...
April 2024: Journal of Cellular and Molecular Medicine
https://read.qxmd.com/read/38652092/macrophage-derived-extracellular-vesicles-alter-cardiac-recovery-and-metabolism-in-a-rat-heart-model-of-donation-after-circulatory-death
#31
JOURNAL ARTICLE
Selianne Graf, Vanessa Biemmi, Maria Arnold, Adrian Segiser, Anja Müller, Natalia Méndez-Carmona, Manuel Egle, Matthias Siepe, Lucio Barile, Sarah Longnus
Conditions to which the cardiac graft is exposed during transplantation with donation after circulatory death (DCD) can trigger the recruitment of macrophages that are either unpolarized (M0) or pro-inflammatory (M1) as well as the release of extracellular vesicles (EV). We aimed to characterize the effects of M0 and M1 macrophage-derived EV administration on post-ischaemic functional recovery and glucose metabolism using an isolated rat heart model of DCD. Isolated rat hearts were subjected to 20 min aerobic perfusion, followed by 27 min global, warm ischaemia or continued aerobic perfusion and 60 min reperfusion with or without intravascular administration of EV...
April 2024: Journal of Cellular and Molecular Medicine
https://read.qxmd.com/read/38652072/investigation-of-basolateral-targeting-micelles-for-drug-delivery-applications-in-polycystic-kidney-disease
#32
JOURNAL ARTICLE
Yi Huang, Ali Osouli, Jessica Pham, Valeria Mancino, Colette O'Grady, Taranatee Khan, Baishali Chaudhuri, Nuria M Pastor-Soler, Kenneth R Hallows, Eun Ji Chung
Autosomal dominant polycystic kidney disease (ADPKD) is a complex disorder characterized by uncontrolled renal cyst growth, leading to kidney function decline. The multifaceted nature of ADPKD suggests that single-pathway interventions using individual small molecule drugs may not be optimally effective. As such, a strategy encompassing combination therapy that addresses multiple ADPKD-associated signaling pathways could offer synergistic therapeutic results. However, severe off-targeting side effects of small molecule drugs pose a major hurdle to their clinical transition...
April 23, 2024: Biomacromolecules
https://read.qxmd.com/read/38652069/variable-clinical-courses-of-varicella-zoster-virus-infection-related-or-vaccination-related-bone-marrow-failure
#33
JOURNAL ARTICLE
Vasil Toskov, Annamaria Cseh, Alexander Claviez, Beatrice Drexler, Natalia Rotari, Stephan Schwarz-Furlan, Matthias Braun, Peter Bader, Peter Lang, Rita Beier, Bernhard Erdlenbruch, Monika Führer, Miriam Erlacher, Charlotte M Niemeyer, Brigitte Strahm, Ayami Yoshimi
We report 5 children with bone marrow failure (BMF) after primary varicella zoster virus (VZV) infection or VZV vaccination, highlighting the highly variable course. Two patients were treated with intravenous immunoglobulins; one had a slow hematologic recovery, and the other was rescued by allogeneic hematopoietic stem cell transplantation (HSCT). Of the 2 patients treated with immunosuppressive therapy with antithymocyte globulin and cyclosporine, one had a complete response, and the other was transplanted for nonresponse...
April 23, 2024: Journal of Pediatric Hematology/oncology
https://read.qxmd.com/read/38652054/car-t-therapy-followed-by-hematopoietic-stem-cell-transplantation-can-improve-survival-in-children-relapsed-refractory-philadelphia-chromosome-positive-b-cell-acute-lymphoblastic-leukemia
#34
JOURNAL ARTICLE
Yao Li, Guan-Hua Hu, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Pan Suo, Yu Wang, Yi-Fei Cheng, Xiao-Jun Huang
BACKGROUND: Philadelphia chromosome (Ph)-positive B-cell acute lymphoblastic leukemia (ALL) has a high complete remission (CR) rate, but relapse and prolonged measurable residual disease remain serious problems. We sought to describe the CR rate measurable residual disease negative rate and address the results and safety of pediatric patients who underwent after receiving chimeric antigen receptor (CAR) specific for CD19 (CAR-19) followed by hematopoietic stem cell transplantation (HSCT) for the treatment of Ph-positive ALL...
April 23, 2024: Journal of Pediatric Hematology/oncology
https://read.qxmd.com/read/38652038/a-first-in-human-phase-1-study-of-a-tumor-directed-rna-interference-drug-against-hif2%C3%AE-in-patients-with-advanced-clear-cell-renal-cell-carcinoma
#35
JOURNAL ARTICLE
James Brugarolas, Gregory Obara, Kathryn E Beckermann, Brian Rini, Elaine T Lam, James Hamilton, Thomas Schluep, Min Yi, So Wong, Zhongping Lily Mao, Erick Gamelin, Nizar M Tannir
PURPOSE: ARO-HIF2 is an siRNA drug designed to selectively target hypoxia-inducible factor-2α (HIF2α) interrupting downstream pro-oncogenic signaling in clear cell renal cell carcinoma (ccRCC). The aims of this Phase 1 study (AROHIF21001) were to evaluate safety, tolerability, pharmacokinetics, and establish a recommended Phase 2 dose. PATIENTS AND METHODS: Subjects with ccRCC and progressive disease after at least 2 prior therapies that included VEGF and immune checkpoint inhibitors were progressively enrolled into dose-escalation cohorts of ARO-HIF2 administered intravenously at 225, 525, or 1,050 mg weekly...
April 23, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38652008/value-based-payment-and-financing-for-cell-and-gene-therapies-challenges-and-potential-solutions
#36
EDITORIAL
James X Zhang, Lisa R Shugarman
No abstract text is available yet for this article.
April 23, 2024: Journal of Medical Economics
https://read.qxmd.com/read/38651976/plain-language-summary-of-the-karmma-3-study-of-ide-cel-or-standard-of-care-regimens-in-people-with-relapsed-or-refractory-multiple-myeloma
#37
REVIEW
Paula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K Nooka, Salomon Manier, Natalie Callander, Luciano J Costa, Ravi Vij, Nizar J Bahlis, Philippe Moreau, Scott R Solomon, Michel Delforge, Jesus Berdeja, Anna Truppel-Hartmann, Zhihong Yang, Linda Favre-Kontula, Fan Wu, Julia Piasecki, Mark Cook, Sergio Giralt
WHAT IS THIS SUMMARY ABOUT?: This plain language summary describes the results of a Phase 3 study called KarMMa-3. In this ongoing study, researchers looked at a relatively new treatment for people with multiple myeloma, a type of blood cancer, whose cancer got worse despite treatment (refractory) or had cancer that at first improved with treatment, but eventually stopped responding (relapsed). HOW WAS THIS STUDY CONDUCTED?: In the KarMMa-3 study, people with relapsed or refractory multiple myeloma received either a one-time infusion of a new treatment, named ide-cel, or one of the standard of care regimens currently available for patients with this cancer...
April 23, 2024: Future Oncology
https://read.qxmd.com/read/38651918/codelivery-of-cpt-and-siphb1-with-gsh-ros-dual-responsive-hybrid-nanoparticles-based-on-a-12-anen-3-derived-lipid-for-synergistic-lung-cancer-therapy
#38
JOURNAL ARTICLE
Ya-Xuan Liang, Xue-Yi Sun, De-Zhong Xu, Yi-Nan Gao, Quan Tang, Zhong-Lin Lu, Yang Liu
The combination of small-interfering RNA (siRNA)-mediated gene silencing and chemotherapeutic agents for lung cancer treatment has attracted widespread attention in terms of a greater therapeutic effect, minimization of systemic toxicity, and inhibition of multiple drug resistance (MDR). In this work, three amphiphiles, CBN1 - CBN3 , were first designed and synthesized as a camptothecin (CPT) conjugate and gene condensation agents by the combination of CPT prodrugs and di(triazole-[12]aneN3 ) through the ROS-responsive phenylborate ester and different lengths of alkyl chains (with 6, 9, 12 carbon chains for CBN1 - CBN3 , respectively)...
April 23, 2024: ACS Applied Bio Materials
https://read.qxmd.com/read/38651882/novel-antimony-based-antimicrobial-drug-targets-membranes-of-gram-positive-and-gram-negative-bacterial-pathogens
#39
JOURNAL ARTICLE
Tarosha Salpadoru, Kevin E Pinks, Jacob A Lieberman, Kaitlyn Cotton, Karen L Wozniak, Nikolay Gerasimchuk, Marianna A Patrauchan
UNLABELLED: Antimicrobial resistance (AMR) poses a significant worldwide public health crisis that continues to threaten our ability to successfully treat bacterial infections. With the decline in effectiveness of conventional antimicrobial therapies and the lack of new antibiotic pipelines, there is a renewed interest in exploring the potential of metal-based antimicrobial compounds. Antimony-based compounds with a long history of use in medicine have re-emerged as potential antimicrobial agents...
April 23, 2024: Microbiology Spectrum
https://read.qxmd.com/read/38651852/vitiligo-as-a-first-sign-of-vogt-koyanagi-harada-disease
#40
JOURNAL ARTICLE
Marija Vukojević, Nenad Vukojevic, Ante Vuković, Borna Rupčić, Mislav Blažević, Ante Blažević
Vogt-Koyanagi-Harada (VKH) disease is a multisystem disorder characterized by bilateral granulomatous panuveitis resulting in serous retinal detachments, disk edema, and a sunset glow fundus development. Furthermore, it is associated with various extraocular findings, such as tinnitus, hearing loss, vertigo, poliosis, and vitiligo (1). VKH is considered to be an autoimmune disease mediated by T-cells targeting melanocyte antigen tyrosinase peptide (2). Moreover, VKH more often occurs in individuals with a genetic predisposition to the disease, including those of Asian and Hispanic heritage (3)...
December 2023: Acta Dermatovenerologica Croatica: ADC
keyword
keyword
159283
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.